Markets:

Overview

News

Currencies

International

Treasuries

Amphastar Pharmaceuticals, Inc. - Common Stock (NQ:AMPH)

26.46 +0.54 (+2.08%)

Streaming Delayed Price Updated: 1:47 PM EST, Jan 26, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Headline News about Amphastar Pharmaceuticals, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 Next >

Why Amphastar Pharmaceuticals (AMPH) Stock Is Nosediving

January 15, 2026

Shares of pharmaceutical company Amphastar Pharmaceuticals (NASDAQAMPH) fell 5.3% in the afternoon session after a Bank of America analyst lowered the firm's price target on the shares and reports...

Via StockStory

2 Reasons to Avoid AMPH and 1 Stock to Buy Instead

January 14, 2026

Amphastar Pharmaceuticals has had an impressive run over the past six months as its shares have beaten the S&P 500 by 19.5%. The stock now trades at $27.76, marking a 31% gain. This was partly due to...

Via StockStory

Topics Stocks Supply Chain

1 Profitable Stock Worth Your Attention and 2 Facing Headwinds

January 13, 2026

While profitability is essential, it doesn’t guarantee long-term success. Some companies that rest on their margins will lose ground as competition intensifies - as Jeff Bezos said, "Your margin is my...

Via StockStory

Earnings Scheduled For November 6, 2025 ↗

November 06, 2025

Via Benzinga

Why Amphastar Pharmaceuticals (AMPH) Stock Is Trading Up Today

January 12, 2026

Shares of pharmaceutical company Amphastar Pharmaceuticals (NASDAQAMPH) jumped 5.8% in the afternoon session after the company announced it had entered into an exclusive license agreement with Nanjing...

Via StockStory

3 Low-Volatility Stocks We Find Risky

January 07, 2026

Stability is great, but low-volatility stocks may struggle to deliver market-beating returns over time as they sometimes underperform during bull markets.

Via StockStory

Amphastar Director Sells 16,679 Shares for $441,800 ↗

December 23, 2025

Amphastar is down big in 2025, but recently announced positive FDA-related news.

Via The Motley Fool

Topics Regulatory Compliance

3 Healthcare Stocks with Questionable Fundamentals

December 15, 2025

Healthcare companies are pushing the status quo by innovating in areas like drug development and digital health. Shareholders who bet on the industry have been rewarded lately as healthcare stocks have...

Via StockStory

Topics Stocks

2 Russell 2000 Stocks for Long-Term Investors and 1 Facing Challenges

December 11, 2025

Small-cap stocks in the Russell 2000 (^RUT) can be a goldmine for investors looking beyond the usual large-cap names. But with less stability and fewer resources than their bigger counterparts, these...

Via StockStory

1 Stock Under $50 Worth Your Attention and 2 We Brush Off

December 08, 2025

Stocks in the $10-50 range offer a sweet spot between affordability and stability as they’re typically more established than penny stocks. But their headline prices don’t guarantee quality, and...

Via StockStory

Amphastar Pharmaceuticals (AMPH) Stock Trades Up, Here Is Why

December 03, 2025

Shares of pharmaceutical company Amphastar Pharmaceuticals (NASDAQAMPH) jumped 3.7% in the afternoon session after positive analyst sentiment and technical trading indicators pointed to potential...

Via StockStory

Topics Economy

Amphastar (AMPH) Q3 2025 Earnings Call Transcript ↗

November 27, 2025

Amphastar (AMPH) Q3 2025 Earnings Call Transcript

Via The Motley Fool

Topics Earnings

The Ensign Group, Illumina, and Amphastar Pharmaceuticals Shares Skyrocket, What You Need To Know

November 21, 2025

A number of stocks jumped in the afternoon session after comments from a key Federal Reserve official bolstered hopes for an interest rate cut. New York Federal Reserve President John Williams stated...

Via StockStory

Topics Economy

Unpacking Q3 Earnings: Amneal (NASDAQ:AMRX) In The Context Of Other Generic Pharmaceuticals Stocks

November 19, 2025

Looking back on generic pharmaceuticals stocks’ Q3 earnings, we examine this quarter’s best and worst performers, including Amneal (NASDAQ:AMRX) and its peers.

Via StockStory

Topics Artificial Intelligence Intellectual Property

3 Small-Cap Stocks with Questionable Fundamentals

November 17, 2025

Small-cap stocks can be incredibly lucrative investments because their lack of analyst coverage leads to frequent mispricings. However, these businesses (and their stock prices) often stay small...

Via StockStory

5 Must-Read Analyst Questions From Amphastar Pharmaceuticals’s Q3 Earnings Call

November 13, 2025

Amphastar Pharmaceuticals' third quarter results for 2025 came in ahead of Wall Street's revenue and profit expectations, despite essentially flat sales compared to the prior year. The quarter was...

Via StockStory

Topics Earnings

Reflecting On Generic Pharmaceuticals Stocks’ Q3 Earnings: Viatris (NASDAQ:VTRS)

November 12, 2025

Wrapping up Q3 earnings, we look at the numbers and key takeaways for the generic pharmaceuticals stocks, including Viatris (NASDAQ:VTRS) and its peers.

Via StockStory

Topics Artificial Intelligence Intellectual Property

Why Amphastar Pharmaceuticals (AMPH) Stock Is Trading Up Today

November 12, 2025

Shares of pharmaceutical company Amphastar Pharmaceuticals (NASDAQAMPH) jumped 3.9% in the afternoon session after the stock's positive momentum continued as the company reported impressive financial...

Via StockStory

Topics Artificial Intelligence Supply Chain

Generic Pharmaceuticals Q3 Earnings: Amphastar Pharmaceuticals (NASDAQ:AMPH) Simply the Best

November 11, 2025

Earnings results often indicate what direction a company will take in the months ahead. With Q3 behind us, let’s have a look at Amphastar Pharmaceuticals (NASDAQ:AMPH) and its peers.

Via StockStory

Topics Artificial Intelligence Intellectual Property

Why Are Amphastar Pharmaceuticals (AMPH) Shares Soaring Today

November 10, 2025

Shares of pharmaceutical company Amphastar Pharmaceuticals (NASDAQAMPH) jumped 10.9% in the afternoon session after the stock's positive momentum continued as the company reported third-quarter...

Via StockStory

Topics Artificial Intelligence Supply Chain

AMPH Q3 Deep Dive: Pipeline Expansion and Core Product Growth Offset Margin Pressures

November 10, 2025

Pharmaceutical company Amphastar Pharmaceuticals (NASDAQAMPH) reported Q3 CY2025 results topping the market’s revenue expectations, but sales were flat year on year at $191.8 million. Its non-GAAP...

Via StockStory

Why Amphastar Pharmaceuticals (AMPH) Stock Is Up Today

November 07, 2025

Shares of pharmaceutical company Amphastar Pharmaceuticals (NASDAQAMPH) jumped 4.9% in the afternoon session after the company reported third-quarter 2025 financial results that surpassed analyst...

Via StockStory

Topics Artificial Intelligence Economy Government

The Analyst Verdict: Amphastar Pharma In The Eyes Of 4 Experts ↗

November 07, 2025

Via Benzinga

Amphastar Pharmaceuticals (NASDAQ:AMPH) Delivers Strong Q3 Numbers

November 06, 2025

Pharmaceutical company Amphastar Pharmaceuticals (NASDAQAMPH) reported revenue ahead of Wall Streets expectations in Q3 CY2025, but sales were flat year on year at $191.8 million. Its non-GAAP profit...

Via StockStory

Topics Artificial Intelligence Supply Chain

Amphastar Pharmaceuticals (AMPH) To Report Earnings Tomorrow: Here Is What To Expect

November 04, 2025

Via StockStory

1 of Wall Street’s Favorite Stock to Target This Week and 2 That Underwhelm

October 30, 2025

Wall Street is overwhelmingly bullish on the stocks in this article, with price targets suggesting significant upside potential. However, it’s worth remembering that analysts rarely issue sell ratings,...

Via StockStory

Topics Economy

2 Reasons AMPH is Risky and 1 Stock to Buy Instead

October 27, 2025

Since April 2025, Amphastar Pharmaceuticals has been in a holding pattern, floating around $24.52. The stock also fell short of the S&P 500’s 22.9% gain during that period.

Via StockStory

Topics Economy Government Stocks

Demystifying Amphastar Pharma: Insights From 4 Analyst Reviews ↗

October 22, 2025

Via Benzinga

Align Technology, Envista, Centene, Amphastar Pharmaceuticals, and Oscar Health Shares Plummet, What You Need To Know

October 10, 2025

A number of stocks fell in the afternoon session after worries over worsening trade relations with China were triggered by critical comments from President Donald Trump.

Via StockStory

Topics Economy Government World Trade

Teva, Viatris On Investor Watch As White House Spares Generic Drugs From Tariffs ↗

October 09, 2025

The Trump administration backs off plans to impose tariffs on generic drugs after internal debate over price impacts and supply concerns.

Via Benzinga

Topics Government World Trade

< Previous 1 2 3 4 5 6 7 8 9 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.